{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:14:22Z","timestamp":1777659262965,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00774-020-01119-9","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T09:03:59Z","timestamp":1594803839000},"page":"848-858","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status"],"prefix":"10.1007","volume":"38","author":[{"given":"Toshitsugu","family":"Sugimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Hosoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Takami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"1119_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.chembiol.2013.12.016","volume":"21","author":"DD Bikle","year":"2014","unstructured":"Bikle DD (2014) Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 21:319\u2013329","journal-title":"Chem Biol"},{"key":"1119_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-016-0805-4","volume":"35","author":"R Okazaki","year":"2017","unstructured":"Okazaki R, Ozono K, Fukumoto S, Inoue D, Yamauchi M, Minagawa M, Michigami T, Takeuchi Y, Matsumoto T, Sugimoto T (2017) Assessment criteria for vitamin D deficiency\/insufficiency in Japan: proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research and the Japan Endocrine Society [Opinion]. J Bone Miner Metab 35:1\u20135","journal-title":"J Bone Miner Metab"},{"key":"1119_CR3","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911\u20131930","journal-title":"J Clin Endocrinol Metab"},{"key":"1119_CR4","unstructured":"Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium (2011) Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press (US). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK56070\/. Accessed 11 October 2019"},{"key":"1119_CR5","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00198-010-1285-3","volume":"21","author":"B Dawson-Hughes","year":"2010","unstructured":"Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burckhardt P, Fuleihan GE, Josse RG, Lips P, Morales-Torres J, Yoshimura N (2010) IOF position statement: vitamin D recommendations for older adults. Osteoporos Int 21:1151\u20131154","journal-title":"Osteoporos Int"},{"key":"1119_CR6","doi-asserted-by":"publisher","first-page":"E610","DOI":"10.1503\/cmaj.080663","volume":"182","author":"DA Hanley","year":"2010","unstructured":"Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD, Cole DEC, Atkinson SA, Josse RG, Feldman S, Kline GA, Rosen C, Guidelines Committee of the Scientific Advisory Council of Osteoporosis Canada (2010) Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 182:E610\u2013E618","journal-title":"CMAJ"},{"key":"1119_CR7","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, NO Foundation (2014) Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359\u20132381","journal-title":"Osteoporos Int"},{"issue":"6 Suppl","key":"1119_CR8","doi-asserted-by":"publisher","first-page":"1706S","DOI":"10.1093\/ajcn\/80.6.1706S","volume":"80","author":"RP Heaney","year":"2004","unstructured":"Heaney RP (1709S) Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 80(6 Suppl):1706S\u20131709S","journal-title":"Am J Clin Nutr"},{"key":"1119_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00223-009-9295-x","volume":"85","author":"M Ishijima","year":"2009","unstructured":"Ishijima M, Sakamoto Y, Yamanaka M, Tokita A, Kitahara K, Kaneko H, Kurosawa H (2009) Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 85:398\u2013404","journal-title":"Calcif Tissue Int"},{"key":"1119_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00774-018-0931-2","volume":"37","author":"R Okazaki","year":"2019","unstructured":"Okazaki R, Muraoka R, Maehara M, Inoue D (2019) Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis. J Bone Miner Metab 37:185\u2013197","journal-title":"J Bone Miner Metab"},{"key":"1119_CR11","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","volume":"23","author":"AS Carmel","year":"2012","unstructured":"Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is \u226533 ng\/ml. Osteoporosis Int 23:2479\u20132487","journal-title":"Osteoporosis Int"},{"key":"1119_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00198-008-0650-y","volume":"20","author":"S Adami","year":"2009","unstructured":"Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, Minisola S, Rossini M (2009) Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 20:239\u2013244","journal-title":"Osteoporos Int"},{"key":"1119_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2012.03.026","volume":"51","author":"P Peris","year":"2012","unstructured":"Peris P, Mart\u00ednez-Ferrer A, Monegal A, Mart\u00ednez de Osaba MJ, Muxi A, Gua\u00f1abens N (2012) 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 51:54\u201358","journal-title":"Bone"},{"key":"1119_CR14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00198-016-3848-4","volume":"28","author":"T Mawatari","year":"2017","unstructured":"Mawatari T, Muraoka R, Iwamoto Y (2017) Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials. Osteoporos Int 28:1279\u20131286","journal-title":"Osteoporos Int"},{"key":"1119_CR15","doi-asserted-by":"crossref","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","DOI":"10.1016\/S0140-6736(96)07088-2"},{"key":"1119_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s001980050214","volume":"10","author":"M Shiraki","year":"1999","unstructured":"Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10:183\u2013192","journal-title":"Osteoporos Int"},{"key":"1119_CR17","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"1119_CR18","first-page":"469","volume":"22","author":"K Kushida","year":"2004","unstructured":"Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y, Orimo H (2004) A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab 22:469\u2013478","journal-title":"J Bone Miner Metab"},{"key":"1119_CR19","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1210\/jc.2003-022029","volume":"88","author":"C Cooper","year":"2003","unstructured":"Cooper C, Emkey RD, McDonald RH, Hawker G, Bianchi G, Wilson K, Schimmer RC (2003) Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:4609\u20134615","journal-title":"J Clin Endocrinol Metab"},{"key":"1119_CR20","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"1119_CR21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gl\u00fcer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"1119_CR22","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"SL Silverman","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923\u20131934","journal-title":"J Bone Miner Res"},{"key":"1119_CR23","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"1119_CR24","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00198-008-0816-7","volume":"20","author":"T Matsumoto","year":"2009","unstructured":"Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429\u20131437","journal-title":"Osteoporos Int"},{"key":"1119_CR25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059\u20131066","journal-title":"J Bone Miner Res"},{"key":"1119_CR26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial\u00a0(2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"1119_CR27","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99:2599\u20132607","journal-title":"J Clin Endocrinol Metab"},{"key":"1119_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s007740050038","volume":"16","author":"H Orimo","year":"1998","unstructured":"Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y (1998) The Committee of the Japanese Society for Bone and Mineral Research for Development of Diagnostic Criteria of Osteoporosis. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139\u2013150","journal-title":"J Bone Miner Metab"},{"key":"1119_CR29","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jbmr.5650110716","volume":"11","author":"HK Genant","year":"1996","unstructured":"Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis the Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984\u2013996","journal-title":"J Bone Miner Res"},{"key":"1119_CR30","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1210\/jc.2005-0290","volume":"90","author":"DM Antoniucci","year":"2005","unstructured":"Antoniucci DM, Vittinghoff E, Blackwell T, Black DM, Sellmeyer DE (2005) Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab 90:4566\u20134572","journal-title":"J Clin Endocrinol Metab"},{"key":"1119_CR31","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00198-008-0799-4","volume":"20","author":"DM Antoniucci","year":"2009","unstructured":"Antoniucci DM, Vittinghoff E, Palermo L, Black DM, Sellmeyer DE (2009) Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos Int 20:1259\u20131266","journal-title":"Osteoporos Int"},{"key":"1119_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00198-010-1213-6","volume":"22","author":"K Nakamura","year":"2011","unstructured":"Nakamura K, Saito T, Oyama M, Oshiki R, Kobayashi R, Nishiwaki T, Nashimoto M, Tsuchiya Y (2011) Vitamin D sufficiency is associated with low incidence of limb and vertebral fractures in community-dwelling elderly Japanese women: the Muramatsu Study. Osteoporos Int 22:97\u2013103","journal-title":"Osteoporos Int"},{"key":"1119_CR33","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s00774-013-0520-3","volume":"32","author":"S Tanaka","year":"2014","unstructured":"Tanaka S, Kuroda T, Yamazaki Y, Shiraki Y, Yoshimura N, Shiraki M (2014) Serum 25-hydroxyvitamin D below 25 ng\/mL is a risk factor for long bone fracture comparable to bone mineral density in Japanese postmenopausal women. J Bone Mineral Metab 32:514\u2013523","journal-title":"J Bone Mineral Metab"},{"key":"1119_CR34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.7326\/0003-4819-149-4-200808190-00005","volume":"149","author":"JA Cauley","year":"2008","unstructured":"Cauley JA, Lacroix AZ, Wu L, Horwitz M, Danielson ME, Bauer DC, Lee JS, Jackson RD, Robbins JA, Wu C, Stanczyk FZ, LeBoff MS, Wactawski-Wende J, Sarto G, Ockene J, Cummings SR (2008) Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 149:242\u2013250","journal-title":"Ann Intern Med"},{"key":"1119_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1359\/jbmr.071003","volume":"23","author":"AC Looker","year":"2008","unstructured":"Looker AC, Mussolino ME (2008) Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res 23:143\u2013150","journal-title":"J Bone Miner Res"},{"key":"1119_CR36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.bone.2007.11.002","volume":"42","author":"NM van Schoor","year":"2008","unstructured":"van Schoor NM, Visser M, Pluijm SMF, Kuchuk N, Smit JH, Lips P (2008) Vitamin D deficiency as a risk factor for osteoporotic fractures. Bone 42:260\u2013266","journal-title":"Bone"},{"key":"1119_CR37","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00198-017-3967-6","volume":"28","author":"J Tamaki","year":"2017","unstructured":"Tamaki J, Iki M, Sato Y, Kajita E, Nishino H, Akiba T, Matsumoto T, Kagamimori S, JPOS Study Group (2017) Total 25-hydroxyvitamin D levels predict fracture risk: results from the 15-year follow-up of the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 28:1903\u20131913","journal-title":"Osteoporos Int"},{"key":"1119_CR38","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3389\/fendo.2018.00782","volume":"9","author":"Z Xie","year":"2019","unstructured":"Xie Z, Xia W, Zhang Z, Wu W, Lu C, Tao S, Wu L, Gu J, Chandler J, Peter S, Yuan H, Wu T, Liao E (2019) Prevalence of vitamin D inadequacy among Chinese postmenopausal women: a nationwide, multicenter, cross-sectional study. Front Endocrinol (Lausanne) 9:782","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1119_CR39","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3945\/ajcn.2008.26182","volume":"88","author":"AC Looker","year":"2008","unstructured":"Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA (2008) Serum 25-hydroxyvitamin D status of the US population: 1988\u20131994 compared with 2000\u20132004. Am J Clin Nutr 88:1519\u20131527","journal-title":"Am J Clin Nutr"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-020-01119-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:13:26Z","timestamp":1626308006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-020-01119-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1119"],"URL":"https:\/\/doi.org\/10.1007\/s00774-020-01119-9","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. T. Sugimoto has received research grants from Astellas Pharma, Eisai, Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Eli Lilly Japan, as well as consulting and\/or lecture fees from Asahi Kasei Pharma Co., Ltd., and Daiichi Sankyo Co., Ltd. Dr. T. Matsumoto has received consulting fees from Daiichi Sankyo Co., Ltd., Astellas Amgen Biopharma Co. Ltd., Chugai Pharmaceutical Co., Ltd., and Teijin Pharma. Dr. T. Hosoi has received consulting fees from Daiichi Sankyo Co., Ltd. Dr. M. Shiraki has received consulting fees from Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Teijin Pharma, Asahi Kasei Pharma Co., Ltd., and MSD. Dr. M. Kobayashi, Dr. N. Okubo, and Dr. H. Takami are employees of Daiichi Sankyo Co., Ltd., Tokyo, Japan. Dr. T. Nakamura acted as a consultant for Teijin Pharma, Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Asahi Kasei Pharma Co., Ltd., and Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}